4-1BB agonist antibody - Roche Innovation Center Zurich

Drug Profile

4-1BB agonist antibody - Roche Innovation Center Zurich

Alternative Names: 4-1BB agonist antibody

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche Innovation Center Zurich
  • Class Antibodies; Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action CD4 agonists; CD8 antigen stimulants; Fibroblast activation protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Cancer in Switzerland (Parenteral) before April 2017
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Roche Innovation Center Zurich plans a clinical trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top